Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Capecitabine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention. Browse Capecitabine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
760
Shown on this page
12
Current sort
Recently updated
Therapy scope
Capecitabine
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Capecitabine. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 397–408 of 760 matching trials for Capecitabine.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

NCT00574171
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
lapatinib, Capecitabine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 2 Interventional

XELOX for Metastatic Breast Cancer

NCT00204776
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine and Oxaliplatin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

NCT00634751
View directory record Official record
Conditions
Pancreatic Neoplasms, Bile Duct Neoplasms
Interventions
Oxaliplatin, Capecitabine, Sorafenib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Not applicable Interventional Results available

Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight

NCT01828554
View directory record Official record
Conditions
Obesity, Neoplasms
Interventions
Xeloda
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

NCT02981342
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Abemaciclib, LY3023414, Gemcitabine, Capecitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
New Haven, Connecticut • Peoria, Illinois • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 2 Interventional

Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer

NCT00205322
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

NCT01783756
View directory record Official record
Conditions
Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
lapatinib ditosylate, everolimus, capecitabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 1Phase 2 Interventional

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

NCT01100463
View directory record Official record
Conditions
Palmar-Plantar Erythrodysesthesia, Breast Cancer
Interventions
Cream, 0.1% Uracil Cream
Drug
Lead sponsor
Nanometics (d.b.a. PHD Biosciences)
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial for Large ER-Negative Breast Cancers

NCT01869192
View directory record Official record
Conditions
Malignant Neoplasm of Female Breast
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Capecitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 1 Interventional

Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases

NCT00858429
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
capecitabine, yttrium Y 90 glass microspheres
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT02352831
View directory record Official record
Conditions
Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Interventions
Tosedostat, Capecitabine, Fresh tissue biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 30, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

NCT01234402
View directory record Official record
Conditions
Breast Cancer
Interventions
Ramucirumab DP, IMC-18F1, Capecitabine
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 30, 2026, 8:42 PM EDT

About this Capecitabine clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Capecitabine.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Capecitabine.